Nivolumab for the Treatment of Advanced Pediatric Malignancies

Nivolumab is an immune checkpoint inhibitor with high antitumor activity in selected neoplasms. The aim of the study was to evaluate the efficacy and safety of nivolumab in pediatric patients with various types of highly malignant advanced tumors. Ten patients with a median age of 15.1 years were in...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-12, Vol.40 (12), p.7095-7100
Main Authors: MarjaŃska, Agata, Drogosiewicz, Monika, Dembowska-BagiŃska, BoŻenna, PawiŃska-WĄsikowska, Katarzyna, Balwierz, Walentyna, Bobeff, Katarzyna, MŁynarski, Wojciech, Mizia-Malarz, Agnieszka, Raciborska, Anna, Wysocki, Mariusz, StyczyŃski, Jan
Format: Article
Language:English
Subjects:
Adolescent
Anticancer properties
Antineoplastic Agents, Immunological - pharmacology
Antineoplastic Agents, Immunological - therapeutic use
Antitumor activity
Brain
Brain tumors
Child
Child, Preschool
Female
Hodgkin's lymphoma
Humans
Immune checkpoint inhibitors
Immunotherapy
Lymphoma
Male
Melanoma
Monoclonal antibodies
Neoplasia
Neoplasms
Neoplasms - drug therapy
Neoplasms - mortality
Nivolumab - pharmacology
Nivolumab - therapeutic use
Patients
Pediatrics
Remission
Sarcoma
Skin cancer
Soft tissue sarcoma
Soft tissues
Survival Analysis
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nivolumab is an immune checkpoint inhibitor with high antitumor activity in selected neoplasms. The aim of the study was to evaluate the efficacy and safety of nivolumab in pediatric patients with various types of highly malignant advanced tumors. Ten patients with a median age of 15.1 years were included in the study. The indications for treatment were: malignant skin melanoma (n=5), brain tumor (n=2), malignant melanoma of the brain (n=1), Hodgkin lymphoma (n=1) and soft tissue sarcoma (n=1). Complete disease remission was observed in 4 patients. Overall survival at 24 months from diagnosis for the entire group was 0.36. Two patients receiving combination therapy of nivolumab and ipilimumab did not achieve a remission. Adverse events of immunotherapy were observed in 4/10 patients. Nivolumab is a promising option in pediatric advanced malignancies. Treatment with immunotherapy was relatively well tolerated, and emerging side-effects were manageable.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14738